Biology of Blood and Marrow Transplantation
Volume 15, Issue 8 , Pages 982-990 , August 2009

A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome

  • Peggy A. Wu

      Affiliations

    • Division of Dermatology, Washington University, St. Louis, Missouri
    • ,
  • Youn H. Kim

      Affiliations

    • Department of Dermatology, Stanford University, Stanford, California
    • ,
  • Phillip W. Lavori

      Affiliations

    • Department of Statistics, Stanford University, Stanford, California
    • ,
  • Richard T. Hoppe

      Affiliations

    • Department of Radiation Oncology, Stanford University, Stanford, California
    • ,
  • Keith E. Stockerl-Goldstein

      Affiliations

    • Division of Oncology, Washington University, St. Louis, Missouri
    • Corresponding Author InformationCorrespondence and reprint requests: Keith E. Stockerl-Goldstein, MD, Department of Medicine, Division of Oncology, Washington University School of Medicine, 660 S. Euclid Avenue, CB 8007, St. Louis, MO 63110.

Received 15 March 2009 ,Accepted 27 April 2009.

References 

  1. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med. 2004;350:1978–1988
  2. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–3785
  3. Horwitz SM, Olsen EA, Duvic M, Porcu P, Kim YH. Review of the treatment of mycosis fungoides and Sézary syndrome: a stage-based approach. J Natl Comp Cancer Netw. 2008;6:436–442
  4. Mycosis Fungoides/Sezary syndrome of the cutaneous T-cell lymphomas. NCCN Practice Guidelines in Oncology v12008. NCCN Practice Guidelines Oncol. 2008.
  5. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139:857–866
  6. Herbert K, Spencer A, Grigg A, et al. Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma. Bone Marrow Transplant. 2004;34:521–525
  7. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991;77:1383–1388
  8. Duarte R, Schmitz N, Servitje O, Sureda A. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant. 2008;41:597–604
  9. Bunn P, Lamberg S. Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep. 1979;63:725–728
  10. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713–1722
  11. Kaplan E, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457–481
  12. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141–1154
  13. Team RDC. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2005.
  14. Guitart J, Wickless SC, Oyama Y, et al. Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma. Arch Dermatol. 2002;138:1359–1365
  15. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109–3115
  16. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068–1073
  17. Lee S, Cho BS, Kim SY, et al. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13:1083–1094
  18. Gassas A, Sung L, Saunders E, Doyle J. Graft-versus-leukemia effect in hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia: significantly lower relapse rate in unrelated transplantation. Bone Marrow Transplant. 2007;40:951–955
  19. Maruyama D, Fukuda T, Kato R, et al. Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen. Biol Blood Marrow Transplant. 2007;13:932–941
  20. Lowsky R, Takahashi T, Liu YP, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med. 2005;353:1321–1331
  21. Soiffer R. Immune modulation and chronic graft-versus-host disease. Bone Marrow Transplant. 2008;42:S66–S69
  22. Sprangers B, Van Wijmeersch B, Fevery S, Waer M, Billiau AD. Experimental and clinical approaches for optimization of the graft-versus-leukemia effect. Nat Clin Pract Oncol. 2007;4:404–414
  23. Liang Y, Liu C, Djeu JY, et al. Beta2 integrins separate graft-versus-host disease and graft-versus-leukemia effects. Blood. 2008;111:954–962
  24. Molina A, Zain J, Arber DA, et al. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol. 2005;23:6163–6171
  25. Zecca M, Prete A, Rondelli R, et al. Chronic graft-versus-host disease in children: incidence, risk factors and impact on outcome. Blood. 2002;100:1192–1200
  26. Alyea E, Neuberg D, Mauch P, et al. Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2002;8:139–144
  27. Molina A, Nademanee A, Arber DA, Forman SJ. Remission of refractory Sezary syndrome after bone marrow transplantation from a matched unrelated donor. Biol Blood Marrow Transplant. 1999;5:400–404
  28. Burt RK, Guitart J, Traynor A, et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect. Bone Marrow Transplant. 2000;25:111–113
  29. Masood N, Russell KJ, Olerud JE, et al. Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation. J Am Acad Dermatol. 2002;47:140–145
  30. Soligo D, Ibatici A, Morandi P, et al. Treatment of advanced mycosis fungoides by allogeneic stem-cell transplantation with a nonmyeloablative regimen. Bone Marrow Transplant. 2003;31:663–666
  31. Koeppel M-C, Stoppa A-M, Resbeut M, et al. Mycosis fungoides and allogeneic bone marrow transplantation. Acta Derm Venereol. 1994;74:331–332
  32. Introcaso CE, Leber B, Greene K, et al. Stem cell transplantation in advanced cutaneous T-cell lymphoma. J Am Acad Dermatol. 2008;58:645–649
  33. Ferra C, Servitje O, Petriz L, et al. Autologous haematopoietic progenitor transplantation in advanced mycosis fungoides. Br J Dermatol. 1999;140:1188–1189
  34. Sterling JC, Marcus R, Burrows NP, Roberts SO. Erythrodermic mycosis fungoides treated with total body irradiation and autologous bone marrow transplantation. Clin Exp Dermatol. 1995;20:73–75
  35. Olavarria E, Child F, Woolford A, et al. T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol. 2001;114:624–631
  36. Russell-Jones R, Child F, Olavarria E, et al. Autologous peripheral blood stem cell transplantation in tumor-stage mycosis fungoides: predictors of disease-free survival. Ann N Y Acad Sci. 2001;941:147–154
  37. Bigler RD, Crilley P, Micaily B, et al. Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant. 1991;7:133–137
  38. Chen YC, Wang CH, Huang SC, et al. Autologous bone marrow transplantation after supralethal dose of total body irradiation in a case of mycosis fungoides. Taiwan Yi Xue Hui Za Zhi. 1986;85:304–314
  39. Ingen-Housz-Oro S, Bachelez H, Verola O, et al. High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma. Bone Marrow Transplant. 2004;33:629–934

 Financial disclosure: See Acknowledgments on page 989.

PII: S1083-8791(09)00218-3

doi: 10.1016/j.bbmt.2009.04.017

Biology of Blood and Marrow Transplantation
Volume 15, Issue 8 , Pages 982-990 , August 2009

Article Tools

* Image Usage & Resolution